Cardio Diagnostics Holdings, Inc. (CDIO)
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $14.8K
- Net income
- -$6.5M
- Total assets
- $7.8M
- Market cap
- $5.8M
- Operating margin
- -43737.5%
- Net margin
- -43832.5%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $14.8K
- Operating expenses
- $6.5M
- Operating income
- -$6.5M
- Net income
- -$6.5M
- EPS (basic)
- $-3.71
- EPS (diluted)
- $-3.71
Balance sheet
- Total assets
- $7.8M
- Current assets
- $5.9M
- Total liabilities
- $793.1K
- Current liabilities
- $604.8K
- Shareholders’ equity
- $7.0M
Cash flow
- Operating cash flow
- -$5.7M
- Investing cash flow
- -$419.3K
- Financing cash flow
- $3.4M
- Net cash flow
- -$2.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $5.8M
- EPS (diluted)
- $-3.71
- Shares outstanding
- 3.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 26, 2022
Cardio Diagnostics Holdings, Inc. (CDIO) Stock Price
- Reported a net loss of $6.5M in FY2025.
- Revenue grew 1461% from FY2022 to FY2025.
- Trading 76% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cardio Diagnostics Holdings, Inc..
Write a review
News about Cardio Diagnostics Holdings, Inc.
News & sentiment via Polygon.io
Cardio Diagnostics Holdings, Inc.: frequently asked questions
Is Cardio Diagnostics Holdings, Inc. an American company?
Cardio Diagnostics Holdings, Inc. is a US-based company headquartered in Chicago, Illinois, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Cardio Diagnostics Holdings, Inc. headquartered?
Cardio Diagnostics Holdings, Inc. is headquartered in Chicago, Illinois, United States.
Is Cardio Diagnostics Holdings, Inc. publicly traded?
Yes — Cardio Diagnostics Holdings, Inc. is a publicly traded company. Its stock trades under the ticker symbol CDIO on the NASDAQ.
What does Cardio Diagnostics Holdings, Inc. do?
Cardio Diagnostics Holdings, Inc. is an American Medical Devices company in the Health & Beauty sector.
